Specify a stock or a cryptocurrency in the search bar to get a summary
Combigene AB
COJ0CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden. Address: Agavagen 52A, Lidingö, Sweden, 181 55
Analytics
WallStreet Target Price
21.63 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures COJ0
Dividend Analytics COJ0
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History COJ0
Stock Valuation COJ0
Financials COJ0
Results | 2019 | Dynamics |